{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:37:27Z","timestamp":1793151447606,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inhibition of the Wnt antagonist sclerostin increases bone mass in patients with osteoporosis and in preclinical animal models. Here we show increased levels of the Wnt antagonist Dickkopf-1 (DKK-1) in animals treated with sclerostin antibody, suggesting a negative feedback mechanism that limits Wnt-driven bone formation. To test our hypothesis that co-inhibition of both factors further increases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations in the Fab region to promote efficient and stable cognate light\u2013heavy chain pairing. We demonstrate that dual inhibition of sclerostin and DKK-1 leads to synergistic bone formation in rodents and non-human primates. Furthermore, by targeting distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity compared with monotherapies. This work supports the potential of this agent both for treatment and prevention of fractures and offers a promising therapeutic approach to reduce the burden of low bone mass disorders.<\/jats:p>","DOI":"10.1038\/ncomms11505","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T05:32:15Z","timestamp":1464327135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":246,"title":["A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair"],"prefix":"10.1038","volume":"7","author":[{"given":"Monica","family":"Florio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Gunasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Salimi-Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin J.","family":"Asuncion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banghua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Lin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ya","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy N.","family":"Duguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennitte","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Pretorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrain","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Brisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua Zhu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"BFncomms11505_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron, R. & Kneissel, M. WNT signalling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179\u2013192 (2013).","journal-title":"Nat. Med."},{"key":"BFncomms11505_CR2","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li, X. et al. Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883\u201319887 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFncomms11505_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1084\/jem.20031454","volume":"199","author":"RL van Bezooijen","year":"2004","unstructured":"van Bezooijen, R. L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805\u2013814 (2004).","journal-title":"J. Exp. Med."},{"key":"BFncomms11505_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577\u2013589 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"BFncomms11505_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans, W. et al. Identification of a 52\u2009kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91\u201397 (2002).","journal-title":"J. Med. Genet."},{"key":"BFncomms11505_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860\u2013869 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"BFncomms11505_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.str.2011.07.005","volume":"19","author":"E Bourhis","year":"2011","unstructured":"Bourhis, E. et al. Wnt antagonists bind through a short peptide to the first beta-propeller domain of LRP5\/6. Structure 19, 1433\u20131442 (2011).","journal-title":"Structure"},{"key":"BFncomms11505_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.devcel.2011.09.003","volume":"21","author":"VE Ahn","year":"2011","unstructured":"Ahn, V. E. et al. Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5\/6. Dev. Cell 21, 862\u2013873 (2011).","journal-title":"Dev. Cell"},{"key":"BFncomms11505_CR9","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/nsmb.2139","volume":"18","author":"Z Cheng","year":"2011","unstructured":"Cheng, Z. et al. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat. Struct. Mol. Biol. 18, 1204\u20131210 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFncomms11505_CR10","doi-asserted-by":"publisher","first-page":"9172","DOI":"10.1074\/jbc.M109.092130","volume":"285","author":"E Bourhis","year":"2010","unstructured":"Bourhis, E. et al. Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J. Biol. Chem. 285, 9172\u20139179 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFncomms11505_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1534-5807(01)00041-7","volume":"1","author":"M Mukhopadhyay","year":"2001","unstructured":"Mukhopadhyay, M. et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev. Cell 1, 423\u2013434 (2001).","journal-title":"Dev. Cell"},{"key":"BFncomms11505_CR12","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1128\/MCB.25.12.4946-4955.2005","volume":"25","author":"M Ai","year":"2005","unstructured":"Ai, M., Holmen, S. L., Van Hul, W., Williams, B. O. & Warman, M. L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell Biol. 25, 4946\u20134955 (2005).","journal-title":"Mol. Cell Biol."},{"key":"BFncomms11505_CR13","doi-asserted-by":"publisher","first-page":"38276","DOI":"10.1074\/jbc.M609509200","volume":"281","author":"MV Semenov","year":"2006","unstructured":"Semenov, M. V. & He, X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281, 38276\u201338284 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFncomms11505_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00223-008-9130-9","volume":"82","author":"W Balemans","year":"2008","unstructured":"Balemans, W. et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif. Tissue Int. 82, 445\u2013453 (2008).","journal-title":"Calcif. Tissue Int."},{"key":"BFncomms11505_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.2249","volume":"44","author":"K Estrada","year":"2012","unstructured":"Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491\u2013501 (2012).","journal-title":"Nat. Genet."},{"key":"BFncomms11505_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412\u2013420 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms11505_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi, D., Jang, G., Stouch, B., Fang, L. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone. Miner. Res. 26, 19\u201326 (2011).","journal-title":"J. Bone. Miner. Res."},{"key":"BFncomms11505_CR18","first-page":"331","volume":"120","author":"NC Munshi","year":"2012","unstructured":"Munshi, N. C. et al. Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression. Blood (ASH Annual Meeting Abstracts) 120, 331 (2012).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFncomms11505_CR19","doi-asserted-by":"crossref","unstructured":"Edenfield, W. J. et al. A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer. J Clin Oncol (ASCO Annual Meeting Abstracts) 32, (suppl. abstr. 8068) (2014).","DOI":"10.1200\/jco.2014.32.15_suppl.8068"},{"key":"BFncomms11505_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer, S. P. et al. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br. J. Haematol. 167, 366\u2013375 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFncomms11505_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"RR Recker","year":"2015","unstructured":"Recker, R. R. et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 30, 216\u2013224 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"BFncomms11505_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky, M. S. et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 25, 948\u2013959 (2010).","journal-title":"J Bone Miner Res."},{"key":"BFncomms11505_CR23","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1002\/jbmr.472","volume":"26","author":"X Li","year":"2011","unstructured":"Li, X. et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J. Bone Miner. Res. 26, 2610\u20132621 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFncomms11505_CR24","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jbmr.307","volume":"26","author":"MS Ominsky","year":"2011","unstructured":"Ominsky, M. S. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 26, 1012\u20131021 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFncomms11505_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bone.2009.06.015","volume":"45","author":"S Bajada","year":"2009","unstructured":"Bajada, S., Marshall, M. J., Wright, K. T., Richardson, J. B. & Johnson, W. E. Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45, 726\u2013735 (2009).","journal-title":"Bone"},{"key":"BFncomms11505_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bone.2014.07.031","volume":"67","author":"M Stolina","year":"2014","unstructured":"Stolina, M. et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone 67, 305\u2013313 (2014).","journal-title":"Bone"},{"key":"BFncomms11505_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.emboj.7600460","volume":"24","author":"MN Chamorro","year":"2005","unstructured":"Chamorro, M. N. et al. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J. 24, 73\u201384 (2005).","journal-title":"EMBO J."},{"key":"BFncomms11505_CR28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrd3581","volume":"10","author":"D Holmes","year":"2011","unstructured":"Holmes, D. Buy buy bispecific antibodies. Nat. Rev. Drug Discov. 10, 798\u2013800 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFncomms11505_CR29","doi-asserted-by":"publisher","first-page":"E252","DOI":"10.1210\/jc.2013-3278","volume":"99","author":"AH van Lierop","year":"2014","unstructured":"van Lierop, A. H., Moester, M. J., Hamdy, N. A. & Papapoulos, S. E. Serum Dickkopf 1 levels in sclerostin deficiency. J. Clin. Endocrinol. Metab. 99, E252\u2013E256 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFncomms11505_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2265.2009.03728.x","volume":"72","author":"AD Anastasilakis","year":"2010","unstructured":"Anastasilakis, A. D. et al. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin. Endocrinol. (Oxf.) 72, 752\u2013757 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFncomms11505_CR31","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1074\/jbc.M705092200","volume":"283","author":"AG Robling","year":"2008","unstructured":"Robling, A. G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. J. Biol. Chem. 283, 5866\u20135875 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFncomms11505_CR32","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido, T. et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146, 4577\u20134583 (2005).","journal-title":"Endocrinology"},{"key":"BFncomms11505_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s007760050010","volume":"5","author":"A Ozaki","year":"2000","unstructured":"Ozaki, A., Tsunoda, M., Kinoshita, S. & Saura, R. Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process. J. Orthop. Sci. 5, 64\u201370 (2000).","journal-title":"J. Orthop. Sci."},{"key":"BFncomms11505_CR34","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1128\/MCB.05980-11","volume":"31","author":"W Wei","year":"2011","unstructured":"Wei, W. et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by \u03b2-catenin. Mol. Cell. Biol. 31, 4706\u20134719 (2011).","journal-title":"Mol. Cell. Biol."},{"key":"BFncomms11505_CR35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jbmr.2152","volume":"29","author":"MS Ominsky","year":"2014","unstructured":"Ominsky, M. S., Niu, Q. T., Li, C., Li, X. & Ke, H. Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Miner. Res. 29, 1424\u20131430 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"BFncomms11505_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti, M. et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371\u2013379 (2009).","journal-title":"Blood"},{"key":"BFncomms11505_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","volume":"39","author":"J Li","year":"2006","unstructured":"Li, J. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754\u2013766 (2006).","journal-title":"Bone"},{"key":"BFncomms11505_CR38","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1371\/journal.pmed.0040249","volume":"4","author":"Y Chen","year":"2007","unstructured":"Chen, Y. et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 4, e249 (2007).","journal-title":"PLoS Med."},{"key":"BFncomms11505_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1359\/jbmr.081206","volume":"24","author":"X Li","year":"2009","unstructured":"Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578\u2013588 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"BFncomms11505_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0022-2836(71)90324-X","volume":"55","author":"B Lee","year":"1971","unstructured":"Lee, B. & Richards, F. M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55, 379\u2013400 (1971).","journal-title":"J. Mol. Biol."},{"key":"BFncomms11505_CR41","doi-asserted-by":"publisher","first-page":"19637","DOI":"10.1074\/jbc.M110.117382","volume":"285","author":"K Gunasekaran","year":"2010","unstructured":"Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637\u201319646 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFncomms11505_CR42","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1074\/jbc.M114.620260","volume":"290","author":"Z Liu","year":"2015","unstructured":"Liu, Z. et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J. Biol. Chem. 290, 7535\u20137562 (2015).","journal-title":"J. Biol. Chem."},{"key":"BFncomms11505_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/btpr.2021","volume":"31","author":"B Estes","year":"2015","unstructured":"Estes, B. et al. Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system. Biotechnol. Prog. 31, 258\u2013267 (2015).","journal-title":"Biotechnol. Prog."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms11505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms11505","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms11505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T06:30:06Z","timestamp":1672813806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms11505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFncomms11505"],"URL":"https:\/\/doi.org\/10.1038\/ncomms11505","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726384148.793519671","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726384148.793531557","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]},"assertion":[{"value":"29 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amgen Inc. funded this study. HZK is a UCB Pharma employee and owns UCB Pharma stock and\/or stock options. All other authors are Amgen Inc. employees and own Amgen Inc. stock and\/or stock options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11505"}}